Abstract
The tumor suppressor activity of the BRCA1 gene product is due, in part, to functional interactions with other tumor suppressors, including p53 and the retinoblastoma (RB) protein. RB binding sites on BRCA1 were identified in the C-terminal BRCT domain (Yarden and Brody, 1999) and in the N-terminus (aa 304–394) (Aprelikova et al., 1999). The N-terminal site contains a consensus RB binding motif, LXCXE (aa 358–362), but the role of this motif in RB binding and BRCA1 functional activity is unclear. In both in vitro and in vivo assays, we found that the BRCA1:RB interaction does not require the BRCA1 LXCXE motif, nor does it require an intact A/B binding pocket of RB. In addition, nuclear co-localization of the endogenous BRCA1 and RB proteins was observed. Over-expression of wild-type BRCA1 (wtBRCA1) did not cause cell cycle arrest but did cause down-regulation of expression of RB, p107, p130, and other proteins (e.g., p300), associated with increased sensitivity to DNA-damaging agents. In contrast, expression of a full-length BRCA1 with an LXCXE inactivating mutation (LXCXE→RXRXH) failed to down-regulate RB, blocked the down-regulation of RB by wtBRCA1, induced chemoresistance, and abrogated the ability of BRCA1 to mediate tumor growth suppression of DU-145 prostate cancer cells. wtBRCA1-induced chemosensitivity was partially reversed by expression of either Rb or p300 and fully reversed by co-expression of Rb plus p300. Our findings suggest that: (1) disruption of the LXCXE motif within the N-terminal RB binding region alters the biologic function of BRCA1; and (2) over-expression of BRCA1 inhibits the expression of RB and RB family (p107 and p130) proteins.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alley MC, Scudieco DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR . 1988 Cancer Res. 48: 589–601
Aprelikova ON, Fang BS, Meissner EG, Cotter S, Campbell M, Kuthiala A, Besho M, Jensen RA, Liu ET . 1999 Proc. Natl. Acad. Sci. USA 96: 11866–11871
Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T . 1998 Nature 391: 597–601
Carroll AG, Voeller HJ, Sugars L, Gelmann EP . 1993 Prostate 23: 123–134
Chai YL, Cui J, Shao N, Shyam E, Reddy P, Rao VN . 1999 Oncogene 18: 263–268
Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, Lee WH . 1996 J. Biol. Chem. 271: 32863–32868
Cress WD, Johnson DG, Nevins JR . 1993 Mol. Cell. Biol. 13: 6314–6325
Dignam JD, Lebovitz RM, Roeder RG . 1983 Nucleic Acids Res. 5: 1475–1489
Doostzadeh-Cizeron J, Evans R, Yin S, Goodrich DW . 1999 Mol. Cell. Biol. 10: 3251–3261
Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM . 1994 Cancer Res. 54: 5824–5830
Fan S, Wang J-A, Meng Q, Yuan R-Q, Ma YX, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM . 1999 Science 284: 1354–1356
Fan S, Wang J-A, Yuan R-Q, Ma YX, Meng Q, Goldberg ID, Rosen EM . 1998 Oncogene 16: 3069–3083
Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin Jr WG, Livingston DM, Orkin SH, Greenberg ME . 1996 Cell 85: 549–561
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE . 1994 Lancet 343: 692–695
Freundlieb S, Baron U, Bonin AL, Gossen M, Bujard H . 1997 Methods Enzymol. 283: 159–173
Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA . 1998 Science 281: 1009–1012
Grant DS, Kleinman HK, Goldberg ID, Bhargava M, Nickoloff BJ, Polverini P, Rosen EM . 1993 Proc. Natl. Acad. Sci. USA 90: 1937–1941
Hakem R, de la Pomba JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW . 1996 Cell 85: 1009–1023
Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA . 1999 Cell 97: 575–586
Herrmann M, Lorenz H-M, Voll R, Grunke M, Weith W, Kalden JR . 1994 Nucleic Acids Res. 22: 5506–5507
Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King M-C, Jensen RA . 1996 Nat. Genet. 12: 298–302
Hsieh JK, Federsdorf S, Kouzarides T, Martin K, Lu X . 1997 Genes Dev. 11: 1840–1852
Kaelin Jr WG, Pallor DC, DeCaprio JA, Kaye FJ, Livingston DM . 1991 Cell 64: 521–532
Lee JO, Russo AA, Pavletich NP . 1998 Nature 391: 859–865
Lin SC, Shapek SX, Lee EY . 1996 Semin. Cancer Biol. 7: 279–289
Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A . 1998 Nature 391: 601–605
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cichran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden, R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MK . 1994 Science 266: 66–71
Monteiro AN, August A, Hanafusa H . 1996 Proc. Natl. Acad. Sci. USA 93: 13595–13599
Ouichi T, Monteiro AN, August A, Aaronson SA, Hanafusa H . 1998 Proc. Natl. Acad. Sci. USA 95: 2302–2306
Rajan JV, Wang M, Marquis ST, Chodosh L . 1996 Proc. Nat. Acad. Sci. USA 93: 13078–13083
Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM . 2000 Proc. Natl. Acad. Sci. USA 97: 1020–1050
Pestell RG, Albanese C, Lee RJ, Watanabe G, Moran E, Johnson J, Jameson JL . 1996 Cell. Growth Differ. 7: 1337–1344
Pomerantz J, Schreiber Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA . 1998 Cell 92: 713–723
Quelle DE, Zindy F, Ashmun RA, Sherr CD . 1995 Cell 83: 993–1000
Samuelson AV, Lowe SW . 1997 Proc. Natl. Acad. Sci. USA 94: 12094–12099
Sarkar FH, Sakr W, Li YW, Macoska J, Ball DE, Crissman JD . 1992 Prostate 21: 145–152
Scully R, Chen J, Plug A, Xiao P, Weaver D, Feunteau J, Ashley T, Livingston D . 1997 Cell 88: 265–275
Shao N, Chai YL, Shyam E, Reddy P, Rao VM . 1996 Oncogene 13: 1–7
Somasundaram K, MacLachlan TK, Burns TF, Sgagias M, Cowan KH, Weber BL, El-Deiry WS . 1999 Oncogene 18: 6605–6614
Somasundaram K, Zhang H, Zeng Y-X, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL, El-Deiry WS . 1997 Nature 389: 187–190
Streuwing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA . 1997 New Engl. J. Med. 336: 1401–1408
Tao W, Levine AJ . 1999 Proc. Natl. Acad. Sci. USA 96: 6937–6941
Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT . 1995 Nat. Genet. 9: 444–450
Tirkkonen M, Johannson O, Agnarsson BA, Olsson H, Ingvarsson S, Karbu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi OP . 1997 Cancer Res. 57: 1222–1227
Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T . 1998 Mol. Cell. 2: 293–304
Wang CY, Petryniak B, Thompson CB, Kaelin WG, Leiden JM . 1993 Science 260: 1330–1335
Wang H, Shao N, Ding OM, Qui J-Q, Reddy ESP, Rao VN . 1997 Oncogene 15: 143–147
Yarden RI, Brody LC . 1999 Proc. Natl. Acad. Sci. USA 96: 4983–4988
Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R . 1998 J. Biol. Chem. 273: 25388–25392
Zalvide J, DeCaprio JA . 1995 Mol. Cell. Biol. 15: 5800–5810
Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL, El-Deiry WS . 1998 Oncogene 16: 1713–1721
Acknowledgements
This research was supported in part by grants from the USPHS (R01-ES09169, RO1-CA80000, and RO1-CA82599), the Elsa U. Pardee Cancer Foundation of Michigan, the New York State Department of Health (EMR), a U.S. Army Career Development Award to S Fan, and a Long Island Jewish Hospital Competitive Pool Award (S Fan).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Fan, S., Yuan, Rq., Ma, Y. et al. Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding. Oncogene 20, 4827–4841 (2001). https://doi.org/10.1038/sj.onc.1204666
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204666
Keywords
This article is cited by
-
Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells
Oncogene (2016)
-
Kaposi’s sarcoma-associated herpesvirus lana2 protein interacts with the pocket proteins and inhibits their sumoylation
Oncogene (2014)
-
Knockdown of ZNF403 inhibits cell proliferation and induces G2/M arrest by modulating cell-cycle mediators
Molecular and Cellular Biochemistry (2012)
-
Transcriptional regulation of BRCA1 expression by a metabolic switch
Nature Structural & Molecular Biology (2010)
-
Caspase-dependent BRCA1 cleavage facilitates chemotherapy-induced apoptosis
Apoptosis (2008)